Get the Stockscreener App
23.83
0.29%
0.07
Pre-market:
23.84
0.01
+0.04%
Galapagos Nv Adr stock is traded at $23.83, with a volume of 296.60K.
It is up +0.29% in the last 24 hours and down -10.95% over the past month.
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
See More
Previous Close:
$23.76
Open:
$23.58
24h Volume:
296.60K
Relative Volume:
1.22
Market Cap:
$1.57B
Revenue:
$282.04M
Net Income/Loss:
$221.88M
P/E Ratio:
7.08
EPS:
3.3658
Net Cash Flow:
$-449.57M
1W Performance:
-0.63%
1M Performance:
-10.95%
6M Performance:
-8.91%
1Y Performance:
-36.74%
1-Day Range:
$23.49
$24.00
1-Week Range:
$23.49
$24.04
52-Week Range:
$23.49
$40.34
Galapagos Nv Adr Stock (GLPG) Company Profile
Compare GLPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
23.83 | 1.57B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Downgrade | Kepler | Hold → Reduce |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-02-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-28-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-24-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-23-23 | Upgrade | Jefferies | Underperform → Hold |
| Nov-07-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-27-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-19-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-06-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-20-21 | Initiated | Deutsche Bank | Buy |
| Apr-14-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-23-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Feb-19-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-19-20 | Initiated | Maxim Group | Buy |
| Oct-21-20 | Downgrade | Goldman | Neutral → Sell |
| Aug-25-20 | Downgrade | Jefferies | Buy → Hold |
| Aug-24-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-19-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| Jul-10-20 | Downgrade | Stifel | Buy → Hold |
| Mar-30-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-25-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-24-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Jan-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-18-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-02-19 | Initiated | BofA/Merrill | Neutral |
| Sep-09-19 | Resumed | Morgan Stanley | Overweight |
| Jul-31-19 | Upgrade | UBS | Neutral → Buy |
| Jul-29-19 | Downgrade | Jefferies | Buy → Hold |
View All
Galapagos Nv Adr Stock (GLPG) Latest News
Galapagos To Spin Off Innovative Medicines Business - Forbes
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga
Galapagos stock downgraded to Reduce on strategic concerns - Investing.com
Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa
Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN
Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK
Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com
Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com
Adaptimmune and Galapagos partner on cancer therapy - Investing.com
Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com
Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com
Morgan Stanley lists biotechs with negative enterprise value, 2022 catalysts (NASDAQ:GLPG) - Seeking Alpha
Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs - Yahoo Finance
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com
AIM tech shares that broke America - Interactive Investor
Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's
The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes
GalapagosAll Time High - Seeking Alpha
Galapagos NV ADR (NQ: GLPG - Financial Content
Galapagos Nv Adr Stock (GLPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):